Innovative Therapy Prapela specializes in a groundbreaking noninvasive stimulation therapy based on Stochastic Resonance, which could be highly appealing to hospitals and clinics seeking advanced neonatal respiratory solutions.

FDA Breakthrough Status Receiving FDA Breakthrough Device Designation positions Prapela for expedited approval and increased credibility, offering sales teams a compelling narrative to promote early adoption and partnership opportunities.

Funding & Recognition With over 8 million dollars in awards and grants supporting clinical evaluation, Prapela demonstrates strong backing and validation, which can foster trust with healthcare providers and potential investors.

Product Expansion The launch of the Prapela SVS baby box indicates product innovation beyond therapy devices, opening avenues to target neonatal care units seeking comprehensive solutions for infant comfort and safety.

Market Positioning Operating in a niche segment with ongoing research and regulatory milestones, Prapela presents an opportunity to collaborate or supply to neonatal intensive care units, hospital systems, and specialty clinics focusing on neonatal health interventions.